期刊
JOURNAL OF CELLULAR BIOCHEMISTRY
卷 112, 期 5, 页码 1384-1391出版社
WILEY
DOI: 10.1002/jcb.23055
关键词
ANGIOGENESIS; INDIRUBIN-3-MONOXIME; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; ENDOTHELIAL CELL
资金
- Ministry of Education, Science and Technology [2010-0004728]
- National Research Foundation of Korea [2010-0004728] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
Although the antiangiogenic activity of indirubin-3-monoxime (I3M), a derivative of a Chinese anti-leukemia medicine, has been demonstrated using transgenic zebrafish, the detail molecular mechanism has not been elicited. To further establish its role in antiangiogenic activity, we tested its potential against human umbilical vein endothelial cells (HUVECs) and the in vivo Matrigel plug model was applied to evaluate new vessel formation. We also investigated the molecular mechanisms of I3M-induced antiangiogenic effects in HUVECs. We found that I3M significantly inhibited HUVEC proliferation (2.5-20 mu M), migration (2.5-20 mu M), and tube formation (10-20 mu M) in HUVECs. The number of microvessels growing from the aortic rings was suppressed by I3M treatment. Moreover, I3M suppressed neovascularization in Matrigel plugs in mice. The underlying antiangiogenic mechanism of I3M was correlated with down-regulation of the vascular endothelial growth factor receptor-2 activation, at least a part. These findings emphasize the potential use of I3M in pathological situations involving stimulated angiogenesis, such as tumor development. J. Cell. Biochem. 112: 1384-1391, 2011. (C) 2011 Wiley-Liss, Inc.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据